Metamark is a privately held company dedicated to improving cancer care by providing the next generation of diagnostic and prognostic testing. Since it’s founding in 2007 by world leaders in cancer biology, molecular diagnostics and personalized medicine, Metamark has evolved into a leader in clinical proteomics – the study of proteins and protein signatures within healthy and diseased cells. Metamark is a leader in the diagnosis and management of prostate cancer, cancer of the bladder and other urologic conditions. For more information, please visit the Metamark website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark.